Johnson & Johnson has entered into a voluntary agreement with the U.S. government to offer significant drug price reductions for American patients in exchange for exemptions from certain import tariffs. Under the terms of the deal, J&J will participate in TrumpRx.gov, a direct-to-patient platform, providing select medicines at discounted rates to millions of consumers. The company will also align its U.S. Medicaid pricing with levels comparable to other developed nations and extend similar price concessions for commercially insured patients. In return, pharmaceutical products manufactured and distributed by J&J will receive relief from new tariff measures the administration implemented earlier this year. This agreement complements J&J’s commitment to invest $55 billion in U.S. manufacturing, research and development, with two new facilities announced in Pennsylvania and North Carolina and a $2 billion biologics plant under construction in Wilson, North Carolina.

Almanack Investment Partners LLC boosted its position in Johnson & Johnson by 29.6% during the third quarter, acquiring an additional 2,985 shares to bring its total stake to 13,074 shares, worth approximately $2.42 million as of the latest 13F filing with the SEC. Other institutional moves include Evolution Wealth Management taking a new $27,000 position and Signature Resources Capital Management expanding its holdings by 262.9% to 254 shares, valued at $47,000. Overall, 69.55% of J&J’s outstanding shares are held by institutional investors and hedge funds, reflecting continued confidence in the company’s diversified portfolio across pharmaceuticals, medical devices and vision care.